Francesco Millo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesco Millo has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Aliana Guerrieri-Gonzaga
Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
12 shared publications - Andrea DeCensi
Division of Medical Oncology, E.O. Galliera Hospital, Genoa, Italy
12 shared publications - Bernardo Bonanni
Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
12 shared publications - Davide Serrano
Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
12 shared publications - Laura Cortesi
Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
12 shared publications - Matteo Lazzeroni
Division of Cancer Prevention and Genetics, IEO, European Institute of Oncology, IRCCS, Milan, Italy
12 shared publications
Latest Publications
- 31 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- p. JCO2600841
Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis
PURPOSE: Tamoxifen 20 mg once-daily reduces the risk of breast cancer recurrence after ductal carcinoma in situ (DCIS), but its use is limited by adverse effects. Lower doses may be effective, but benefit durability and differences according to menopausal status and site of recurrence remain uncertain. METHODS: We conducted an individual-participant pooled analysis of three clinical studies involving women with estrogen receptor–positive or unknown DCIS, microinvasive carcinoma, or high-risk breast lesions. Participants received low-dose tamoxifen (5 mg once daily or 10 mg once-every other day for 2-5 years) or a control intervention. The primary end point was breast cancer–free interval, defined as the first occurrence of any ipsilateral or contralateral invasive breast cancer, DCIS, regional recurrence, or distant recurrence. Hazard ratios (HRs) were estimated with mixed-effects Cox models accounting for between-study variability. RESULTS: Among 1,545 women included with a median follow-up of 9.4 years, low-dose tamoxifen reduced breast cancer events overall, with evidence of treatment heterogeneity according to menopausal status ( P = .01). In postmenopausal women, breast cancer events occurred in 40 of 335 receiving low-dose tamoxifen versus 93 of 401 controls (HR, 0.51 [95% CI, 0.35 to 0.73]), with a 10-year absolute reduction of 11.2%. Among premenopausal women, no significant reduction was observed (HR, 0.90 [95% CI, 0.70 to 1.17]), although contralateral breast cancer was reduced (HR, 0.45 [95% CI, 0.26 to 0.76]). Serious adverse events were infrequent and similar between groups. CONCLUSION: Low-dose tamoxifen was associated with a sustained reduction in breast cancer events, with differences by menopausal status and site of event. These findings support endocrine dose de-escalation to improve the benefit-risk profile of preventive therapy in DCIS and high-risk lesions.
- 31 May 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- p. JCO2600841
Low-Dose Tamoxifen in Noninvasive Breast Neoplasia: Long-Term Results From an Individual-Participant Data Pooled Analysis
PURPOSE: Tamoxifen 20 mg once-daily reduces the risk of breast cancer recurrence after ductal carcinoma in situ (DCIS), but its use is limited by adverse effects. Lower doses may be effective, but benefit durability and differences according to menopausal status and site of recurrence remain uncertain. METHODS: We conducted an individual-participant pooled analysis of three clinical studies involving women with estrogen receptor–positive or unknown DCIS, microinvasive carcinoma, or high-risk breast lesions. Participants received low-dose tamoxifen (5 mg once daily or 10 mg once-every other day for 2-5 years) or a control intervention. The primary end point was breast cancer–free interval, defined as the first occurrence of any ipsilateral or contralateral invasive breast cancer, DCIS, regional recurrence, or distant recurrence. Hazard ratios (HRs) were estimated with mixed-effects Cox models accounting for between-study variability. RESULTS: Among 1,545 women included with a median follow-up of 9.4 years, low-dose tamoxifen reduced breast cancer events overall, with evidence of treatment heterogeneity according to menopausal status ( P = .01). In postmenopausal women, breast cancer events occurred in 40 of 335 receiving low-dose tamoxifen versus 93 of 401 controls (HR, 0.51 [95% CI, 0.35 to 0.73]), with a 10-year absolute reduction of 11.2%. Among premenopausal women, no significant reduction was observed (HR, 0.90 [95% CI, 0.70 to 1.17]), although contralateral breast cancer was reduced (HR, 0.45 [95% CI, 0.26 to 0.76]). Serious adverse events were infrequent and similar between groups. CONCLUSION: Low-dose tamoxifen was associated with a sustained reduction in breast cancer events, with differences by menopausal status and site of event. These findings support endocrine dose de-escalation to improve the benefit-risk profile of preventive therapy in DCIS and high-risk lesions.
- 29 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (6) , 1115-1119
Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase 3 trial in noninvasive breast cancer
Despite the proven efficacy of tamoxifen in breast cancer prevention, its uptake remains limited due to concerns over side effects. A phase 3 trial showed that low-dose tamoxifen (5 mg/d for 3 years) substantially reduces recurrence with minimal toxicity. After 10 years of follow-up, we observed no clinically significant differences in benign gynecological or breast events between the tamoxifen and placebo arms. The uterus was the most frequently affected site (30 cases per arm), followed by the breast (18 cases) and ovary (5 cases vs 3 cases for tamoxifen and placebo, respectively). Endometrial polyps were similarly distributed. Endometrial thickness remained stable in premenopausal women and showed only a mild, non–clinically significant increase in postmenopausal women on tamoxifen (approximately 1.5 mm). Compared with data on standard-dose tamoxifen, rates of benign events were lower. These findings reinforce the favorable safety profile of low-dose tamoxifen.
- 29 August 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (6) , 1115-1119
Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase 3 trial in noninvasive breast cancer
Despite the proven efficacy of tamoxifen in breast cancer prevention, its uptake remains limited due to concerns over side effects. A phase 3 trial showed that low-dose tamoxifen (5 mg/d for 3 years) substantially reduces recurrence with minimal toxicity. After 10 years of follow-up, we observed no clinically significant differences in benign gynecological or breast events between the tamoxifen and placebo arms. The uterus was the most frequently affected site (30 cases per arm), followed by the breast (18 cases) and ovary (5 cases vs 3 cases for tamoxifen and placebo, respectively). Endometrial polyps were similarly distributed. Endometrial thickness remained stable in premenopausal women and showed only a mild, non–clinically significant increase in postmenopausal women on tamoxifen (approximately 1.5 mm). Compared with data on standard-dose tamoxifen, rates of benign events were lower. These findings reinforce the favorable safety profile of low-dose tamoxifen.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Representativeness of Study Participants
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Representativeness of Study Participants
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Mean event rate (per 1000 person-years) stratified by treatment arm, menopausal status, and baseline IGF-I, IGFBP-3, IGF-I/IGFBP-3 at 10 years of follow-up.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Mean event rate (per 1000 person-years) stratified by treatment arm, menopausal status, and baseline IGF-I, IGFBP-3, IGF-I/IGFBP-3 at 10 years of follow-up.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Time-course of estradiol (E2), SHBG, and E2/SHBG molar ratio in post-menopausal women.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Time-course of estradiol (E2), SHBG, and E2/SHBG molar ratio in post-menopausal women.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Kaplan-Meier estimates of cumulative incidence of breast cancer events stratified by baseline biomarker levels and treatment arms.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Kaplan-Meier estimates of cumulative incidence of breast cancer events stratified by baseline biomarker levels and treatment arms.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Main subject characteristics at baseline (n = 406)
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Main subject characteristics at baseline (n = 406)
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Time-course of IGF-I, IGFBP-3, and IGF-I/IGFBP-3 molar ratio in all women.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Time-course of IGF-I, IGFBP-3, and IGF-I/IGFBP-3 molar ratio in all women.
- Open Access
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Time-course of estradiol (E2), SHBG, and E2/SHBG molar ratio in pre-menopausal women.
- 15 May 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Predictive Effect of IGFBP-3 on Low-Dose Tamoxifen Efficacy in Noninvasive Breast Cancer in the Phase III Tam-01 Trial
Time-course of estradiol (E2), SHBG, and E2/SHBG molar ratio in pre-menopausal women.